Research & Educational Resource

Retatrutide Dosage: What Studies Have Actually Investigated

A research-focused review of the retatrutide amounts, treatment groups, study durations, and dose-escalation approaches investigated in published and registered clinical trials.

Important research-use notice

The amounts shown on this page are historical clinical-trial protocols. They are presented to help readers understand the scientific literature and are not recommendations, prescriptions, or instructions for self-administration. Retatrutide is an investigational medicine, and clinical-trial dosing should not be converted into a personal treatment plan.

Molecule

Retatrutide

Also known as LY3437943, an investigational triple GIP/GLP-1/glucagon receptor agonist.

Phase 2

1–12 mg

Weekly subcutaneous target-dose groups were studied in adults with obesity or overweight with weight-related conditions.

Phase 3

4–12 mg

Later TRIUMPH trials investigated target-dose groups including 4 mg, 9 mg, and 12 mg.

Regulatory status

Investigational

Retatrutide is not an FDA-approved medicine for human use.

What Is Retatrutide?

Retatrutide, also identified in clinical research as LY3437943, is an investigational peptide-based medicine designed to activate three hormone receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor.

Unlike medicines that target only one or two of these pathways, retatrutide was developed as a triple-receptor agonist. Clinical researchers have therefore investigated whether coordinated activity across these pathways could influence body weight, glucose regulation, energy metabolism, and related cardiometabolic outcomes.

Importantly, the scientific literature does not contain one universal "retatrutide dose." Different trials have used different target amounts, starting approaches, populations, treatment durations, endpoints, and escalation schedules.

The key point: a dose appearing in a clinical trial tells us what investigators tested under that study's controlled conditions. It does not by itself establish a dose that an individual should take.

What the 2023 Phase 2 Obesity Trial Investigated

The major Phase 2 obesity study was a randomized, double-blind, placebo-controlled trial involving 338 adults with obesity or overweight plus at least one weight-related condition.

Participants were assigned to several retatrutide groups or placebo. The study investigated weekly subcutaneous treatment over 48 weeks and compared multiple target-dose groups.

Study	Population	Investigated target amount	Administration	Study duration	Primary research focus
Phase 2 obesity trial NCT04881760	Adults with obesity or overweight plus a weight-related condition; participants did not have type 2 diabetes.	1 mg	Subcutaneous, once weekly	48 weeks	Change in body weight and safety.
Phase 2 obesity trial	Same trial population.	4 mg	Subcutaneous, once weekly	48 weeks	Weight reduction, tolerability, and safety.
Phase 2 obesity trial	Same trial population.	8 mg	Subcutaneous, once weekly	48 weeks	Weight reduction, tolerability, and safety.
Phase 2 obesity trial	Same trial population.	12 mg	Subcutaneous, once weekly	48 weeks	Weight reduction, tolerability, and safety.

The Phase 2 trial also compared different starting-dose approaches for several higher target-dose groups. The published study reported that gastrointestinal adverse events were more common during dose escalation and were partially reduced when a lower starting amount was used.

The study therefore provides an important research lesson: the target amount and the way participants reached that target were separate parts of the experimental protocol.

What Researchers Observed in Phase 2

The 2023 Phase 2 publication reported substantial dose-associated reductions in body weight over the study period. At 48 weeks, the reported least-squares mean changes were approximately −8.7% for the 1 mg group, −17.1% for the combined 4 mg groups, −22.8% for the combined 8 mg groups, and −24.2% for the 12 mg group, compared with −2.1% for placebo.

These results describe the participants enrolled in that particular randomized trial. They should not be interpreted as a guarantee of an individual result or as evidence that the highest studied amount is appropriate for everyone.

What was measured

Percentage change in body weight
Weight-loss thresholds
Waist circumference
Adverse events
Tolerability during dose escalation
Changes in heart rate

What requires caution

The trial population was selected using eligibility criteria.
The protocol included clinical monitoring.
Formulation and trial supply were controlled.
Participants were not simply self-dosing.
Results from a trial do not establish an individual prescription.
Long-term safety questions remain important.

What Later Phase 3 Studies Investigated

Retatrutide subsequently advanced into the TRIUMPH Phase 3 clinical development program. These studies were substantially larger than the original Phase 2 trial and examined retatrutide in different populations and clinical settings.

By 2026, Lilly had reported topline results from several Phase 3 studies. These results are important because the Phase 3 program used target-dose groups that differed somewhat from the original Phase 2 design.

Phase 3 program	Population studied	Target-dose groups reported	Treatment framework	Status of evidence
TRIUMPH-1 NCT05929066	Adults with obesity or overweight and at least one weight-related comorbidity, without diabetes.	4 mg, 9 mg, 12 mg	Once-weekly subcutaneous clinical-trial treatment with protocol-defined escalation.	Phase 3 topline results reported in 2026.
TRIUMPH-2 NCT05929079	Adults with obesity or overweight and type 2 diabetes.	4 mg, 9 mg, 12 mg	Once-weekly subcutaneous clinical-trial treatment with protocol-defined escalation.	Phase 3 topline results reported in 2026.
TRIUMPH-3 NCT05882045	Adults with severe obesity and established cardiovascular disease, with or without diabetes.	9 mg, 12 mg	Once-weekly subcutaneous clinical-trial treatment with protocol-defined escalation.	Phase 3 topline results reported in 2026.

Important distinction: Phase 3 target-dose groups are not simply a "new recommended dosage." They represent experimental treatment arms selected by the clinical-development program and studied under controlled conditions.

2026 Phase 3 Findings: What Has Been Reported

In May 2026, Lilly announced topline results from TRIUMPH-1. The company reported average body-weight reductions at 80 weeks of approximately 19.0% with the 4 mg target group, 25.9% with the 9 mg target group, and 28.3% with the 12 mg target group.

In July 2026, Lilly reported additional topline Phase 3 findings from TRIUMPH-2 and TRIUMPH-3. In TRIUMPH-2, participants with obesity or overweight and type 2 diabetes had reported average weight reductions of 12.7%, 19.1%, and 20.8% at the 4 mg, 9 mg, and 12 mg target groups respectively at 80 weeks.

These 2026 figures are company-reported topline results. Detailed peer-reviewed publications should be distinguished from corporate press-release summaries when evaluating the complete evidence base.

TRIUMPH-1

4 mg target group: approximately 19.0% average weight reduction
9 mg target group: approximately 25.9%
12 mg target group: approximately 28.3%
Primary reported time point: 80 weeks

TRIUMPH-2

Population included obesity or overweight with type 2 diabetes
4 mg target group: approximately 12.7%
9 mg target group: approximately 19.1%
12 mg target group: approximately 20.8%

Why a Study Dose Is Not the Same as a Personal Dose

Clinical-trial dosing is one part of a larger experimental system. Researchers define eligibility criteria, monitor participants, standardize study procedures, track adverse events, and establish predefined endpoints.

A person obtaining an unapproved product outside a clinical trial does not necessarily have the same product quality, concentration, sterility, pharmacokinetic profile, monitoring, eligibility assessment, or medical supervision.

Population

Trial participants meet specific inclusion and exclusion criteria. Their characteristics may differ substantially from those of someone reading a dosage table online.

Monitoring

Clinical studies include scheduled assessments and safety monitoring that cannot be reproduced by simply copying a published number.

Product control

Investigational clinical-trial material is supplied under study controls. Internet products may not have equivalent identity, purity, potency, sterility, or manufacturing controls.

Route, Formulation, and Product Quality Matter

Retatrutide clinical trials have investigated subcutaneous administration. The fact that a published study reports a milligram amount does not mean that every product labeled with the same number of milligrams is equivalent.

Clinical-trial material

Produced for controlled clinical research
Specified study formulation
Protocol-defined administration
Participant eligibility screening
Safety monitoring
Documented study procedures

Why internet products are different

Identity may require independent verification
Purity and potency may vary
Sterility cannot be assumed from a label
Concentration may differ from expectations
Storage and handling may affect product quality
Unapproved products do not have an FDA-approved label

Safety Findings Reported in Clinical Research

In the Phase 2 obesity study, gastrointestinal adverse events were among the most frequently reported events. Nausea, diarrhea, vomiting, and constipation were reported more frequently in retatrutide groups than in placebo and were generally associated with dose escalation.

The Phase 2 publication also reported dose-dependent increases in heart rate, with the increase peaking around 24 weeks and declining afterward.

These findings are important because the safety profile of an investigational medicine is evaluated together with the dose, treatment duration, participant characteristics, and monitoring framework used in the study.

Do not use this page as an injection or titration guide.

This page intentionally does not provide reconstitution instructions, syringe-unit conversions, injection-volume calculations, or a personal titration schedule. Those details can turn a research summary into an actionable medication-use protocol.

Regulatory Status

Retatrutide remains an investigational medicine. It has been evaluated in clinical trials sponsored by Eli Lilly, but it does not have an FDA-approved prescribing label for routine human use.

The FDA has specifically stated that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. FDA warning letters have also addressed the marketing of unapproved retatrutide products.

Research status matters. Clinical-trial results demonstrate what researchers investigated. They do not create an FDA-approved treatment indication or a consumer dosing recommendation.

How to Read a Retatrutide Dosage Study

When reviewing a paper, registry record, or company-reported result, look beyond the number printed beside "mg." The surrounding study design determines what that number actually means.

Check the population

Obesity without diabetes?
Obesity with type 2 diabetes?
Cardiovascular disease?
Another specific clinical population?
Adults or another age group?

Check the protocol

Target amount
Starting approach
Escalation schedule
Administration route
Treatment duration

Check the outcomes

Weight change
Glucose or A1C
Cardiometabolic markers
Adverse events
Discontinuation rates

Check the evidence quality

Randomized or observational?
Blinded or open-label?
Sample size?
Peer-reviewed publication?
Company topline announcement?

Common Misunderstandings About Retatrutide Dosage

"The highest study dose must be the best dose."

Not necessarily. Higher target groups can produce different efficacy and adverse-event patterns. Dose selection in a clinical trial is a research question involving the balance between efficacy, tolerability, safety, and study objectives.

"If a dose was used in Phase 2, anyone can use it."

No. The Phase 2 dose was part of a controlled experimental protocol involving screened participants, study procedures, monitoring, and investigational product controls.

"4 mg in one study equals 4 mg in every product."

A milligram amount alone does not establish product identity, purity, potency, formulation, sterility, or manufacturing quality.

"Phase 3 means the drug is already approved."

No. Phase 3 is a stage of clinical development. Regulatory approval is a separate process that requires review and an applicable authorization from the relevant regulator.

Frequently Asked Questions

What retatrutide amounts have been investigated in clinical trials?

Published Phase 2 obesity research investigated 1 mg, 4 mg, 8 mg, and 12 mg weekly target-dose groups. Later Phase 3 TRIUMPH studies investigated target-dose groups including 4 mg, 9 mg, and 12 mg, depending on the study population.

Was 12 mg studied in humans?

Yes. A 12 mg weekly target-dose group was included in the 2023 Phase 2 obesity trial, and 12 mg was also included as a target group in subsequent Phase 3 trials.

Does a clinical-trial dose mean that it is a recommended dose?

No. A clinical-trial dose describes an experimental regimen used under a specific research protocol. It is not automatically a prescribing recommendation.

Why did researchers use different retatrutide target amounts?

Clinical development commonly evaluates multiple dose levels to characterize dose-response relationships, efficacy, tolerability, and safety. Different phases and populations can also require different study designs.

Were higher doses associated with more side effects?

In the Phase 2 obesity study, gastrointestinal adverse events were dose-related and were especially associated with the period of dose escalation. The study also reported dose-dependent increases in heart rate.

Is retatrutide FDA approved?

No. Retatrutide remains investigational and does not have an FDA-approved prescribing label for routine human use.

Can I use the numbers on this page to calculate an injection?

No. This page is intentionally limited to research-literature interpretation. It does not provide reconstitution instructions, injection-volume calculations, syringe-unit conversions, or individualized dosing instructions.

Where can researchers verify the clinical trials?

The principal sources include the New England Journal of Medicine publication for the Phase 2 obesity trial and the ClinicalTrials.gov records for the TRIUMPH Phase 3 program. Study identifiers are provided in the sources section below.

Primary Research Sources

The following references are provided so readers can distinguish published clinical research from later trial-registry information and company-reported topline results.

Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine. 2023;389:514–526. DOI: 10.1056/NEJMoa2301972
PubMed: Retatrutide Phase 2 obesity trial. PMID: 37366315
ClinicalTrials.gov: TRIUMPH-1, NCT05929066.
ClinicalTrials.gov: TRIUMPH-2, NCT05929079.
ClinicalTrials.gov: TRIUMPH-3, NCT05882045.
ClinicalTrials.gov: TRIUMPH-Outcomes, NCT06383390.
Eli Lilly: 2026 TRIUMPH-1 Phase 3 topline results and study description.
Eli Lilly: 2026 TRIUMPH-2 and TRIUMPH-3 Phase 3 topline results.
U.S. Food and Drug Administration: Regulatory information concerning unapproved retatrutide and its status under federal compounding requirements.

Research Information Only

This page is provided for scientific and educational reference. It summarizes selected published and registered clinical research and is not medical advice, a prescription, or a treatment protocol.

Clinical-trial amounts should not be copied for personal use. Anyone considering treatment with an investigational medicine should discuss the matter with a qualified healthcare professional and rely on applicable regulatory and clinical guidance.